Creo Medical Group’s (CREO) House Stock Rating Reaffirmed at Shore Capital Group

Creo Medical Group (LON:CREO)‘s stock had its “house stock” rating reaffirmed by equities researchers at Shore Capital Group in a note issued to investors on Thursday,Digital Look reports.

Creo Medical Group Trading Up 2.1%

Shares of LON CREO opened at GBX 12 on Thursday. The company has a current ratio of 5.28, a quick ratio of 2.19 and a debt-to-equity ratio of 6.90. The stock has a market capitalization of £49.48 million, a PE ratio of -12.00 and a beta of 1.22. Creo Medical Group has a twelve month low of GBX 9.22 and a twelve month high of GBX 18.50. The stock has a fifty day simple moving average of GBX 13.76 and a 200-day simple moving average of GBX 12.01.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.